Asia Pacific pharmaceutical CRO market will grow by 9.6% annually with a total addressable market cap of $238.7 billion over 2020-2030 owing to the rising incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 33 tables and 44 figures, this 112-page report Asia Pacific Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical CRO market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
CRO for Pre-clinical Development
CRO for Phase I Trials
CRO for Phase II Trials
CRO for Phase III Trials
CRO for Phase IV Trials
Laboratory Services
Consulting Services
Data Management Services

Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Infectious Diseases
Oncology
Metabolic Disorders
Cardiovascular Disorders
Central Nervous System
Respiratory Disorders
Gastrointestinal Disorders
Other Therapeutic Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Academic Institutes

Geographically, the following national/local markets are fully investigated:
Japan
China
South Korea
Australia
India
Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific pharmaceutical CRO market are assayed quantitatively and qualitatively through GMDs Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Asia Pacific Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)